S
Steven A. Wrighton
Researcher at Eli Lilly and Company
Publications - 161
Citations - 20885
Steven A. Wrighton is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Cytochrome P450 & Microsome. The author has an hindex of 76, co-authored 161 publications receiving 20298 citations. Previous affiliations of Steven A. Wrighton include Indiana University – Purdue University Indianapolis & University of Michigan.
Papers
More filters
Journal ArticleDOI
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.
Peter M. Kuehl,Jiong Zhang,Yvonne S. Lin,Jatinder K. Lamba,Mahfoud Assem,John D. Schuetz,Paul B. Watkins,Ann K. Daly,Steven A. Wrighton,Stephen D. Hall,Patrick Maurel,Mary V. Relling,Cynthia Brimer,Kazuto Yasuda,Raman Venkataramanan,Stephen C. Strom,Kenneth E. Thummel,Mark S. Boguski,Erin G. Schuetz +18 more
TL;DR: CYP3A5 was more frequently expressed in livers of African Americans than in those of Caucasians, and may be the most important genetic contributor to interindividual and interracial differences in CYP3A-dependent drug clearance and in responses to many medicines.
Journal ArticleDOI
The human hepatic cytochromes P450 involved in drug metabolism.
TL;DR: The purpose of this review is to compare and contrast the human P 450s involved in drug metabolism with their related forms in the rat and other experimental species with respect to their relative levels of the various P450s and their metabolic capabilities.
Journal ArticleDOI
The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective
Thorir D. Bjornsson,J. T. Callaghan,Heidi J. Einolf,Volker Fischer,Lawrence Gan,Scott W. Grimm,John Kao,S. Peter King,Gerald T. Miwa,Lan Ni,Gondi N. Kumar,James F. McLeod,R. Scott Obach,Stanley Roberts,Amy L. Roe,Anita Shah,Fred Snikeris,John T. Sullivan,Donald J. Tweedie,José M. Vega,John S Walsh,Steven A. Wrighton +21 more
TL;DR: The intent is to define a minimal best practice for in vitro and in vivo pharmacokinetic drug-drug interaction studies targeted to development (not discovery support) and to defined a data package that can be expected by regulatory agencies in compound registration dossiers.
Journal ArticleDOI
Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man.
TL;DR: It is concluded that the intestinal mucosa contains prominent form(s) of cytochromes P-450 similar to liver cytochrome P- 450p in their structure, function, and some regulatory characteristics.
Journal ArticleDOI
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
J. Andrew Williams,Barbara J. Ring,Barbara J. Ring,Varon E. Cantrell,Varon E. Cantrell,David R. Jones,James A. Eckstein,James A. Eckstein,Kenneth J. Ruterbories,Kenneth J. Ruterbories,Mitchell A. Hamman,Mitchell A. Hamman,Stephen D. Hall,Stephen D. Hall,Steven A. Wrighton,Steven A. Wrighton +15 more
TL;DR: These results demonstrate an equal or reduced metabolic capability for CYP3A5 compared with CYP 3A4 and a significantly lower capability for Cyp3A7.